德展健康(000813) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥89,277,784.01, a decrease of 11.82% compared to ¥101,250,441.65 in the same period last year[5]. - The net loss attributable to shareholders for Q1 2025 was ¥22,114,871.36, representing a 31.60% increase in loss from ¥16,805,072.84 in the previous year[5]. - The basic and diluted earnings per share for Q1 2025 were both -¥0.0104, a decline of 33.33% from -¥0.0078 in the same period last year[5]. - The net loss for the company was ¥29,276,212.82, which is a 35.45% increase from a loss of ¥21,613,891.55 in the same period last year, attributed to decreased interest income and increased credit impairment losses[10]. - Operating profit for the current period was -¥25,695,994.02, compared to -¥16,623,167.08 in the previous period, indicating a worsening of 54.5%[28]. - Net profit for the current period was -¥29,276,212.82, compared to -¥21,613,891.55 in the previous period, representing an increase in losses of 35.5%[28]. Cash Flow and Assets - The net cash flow from operating activities decreased by 20.60% to ¥18,042,709.30 from ¥22,723,297.27 year-on-year[5]. - The net cash flow from investing activities decreased by 82.21% to -¥37,670,373.09, compared to -¥20,673,911.95 in the previous year, mainly due to increased cash payments for fixed assets and intangible assets[10]. - The company’s cash and cash equivalents increased to 2,565,530,124.91 CNY from 2,530,699,274.17 CNY, reflecting a growth of approximately 1.4%[21]. - Cash flow from operating activities generated a net cash inflow of ¥18,042,709.30, down from ¥22,723,297.27 in the previous period, a decrease of 20.5%[31]. - Cash and cash equivalents at the end of the period totaled ¥2,480,454,564.29, a slight decrease from ¥2,731,014,590.64 in the previous period[33]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 65,376[13]. - The largest shareholder, Shanghai Yueye Equity Investment Management Partnership, holds 19.13% of shares, totaling 414,138,066 shares, with 25,250,000 shares frozen[13]. - The second largest shareholder, Xinjiang Kaidi Investment Co., Ltd., holds 18.93% of shares, totaling 409,748,445 shares, with 143,000,000 shares pledged[13]. - The top three shareholders collectively hold over 47% of the company's shares[13]. - The company has a repurchase account holding 28,567,500 shares, representing 1.32% of total shares[15]. - The company is conducting multiple rounds of public auctions for shares held by major shareholders, with recent auctions resulting in the successful sale of 25,250,000 shares[16]. - The report indicates that there are no changes in the top 10 shareholders due to securities lending or borrowing activities[16]. - The company has not issued any preferred shares or disclosed any preferred shareholders[16]. Assets and Liabilities - Total assets at the end of Q1 2025 were ¥5,355,877,868.80, an increase of 0.68% from ¥5,319,833,620.49 at the end of the previous year[5]. - The company’s total liabilities increased to 220,204,515.49 CNY from 154,884,054.36 CNY, representing a significant rise of approximately 42%[23]. - The company’s long-term borrowings amounted to 40,000,000.00 CNY, which was previously zero, indicating new financing activities[23]. - The company’s inventory increased to 209,630,292.48 CNY from 197,873,887.61 CNY, showing a growth of about 5.4%[22]. - The company’s accounts receivable decreased to 217,755,087.09 CNY from 242,227,524.74 CNY, reflecting a decline of approximately 10.1%[21]. Research and Development - The company signed a strategic cooperation framework agreement with Baoshihua Pharmaceutical Technology (Beijing) Co., Ltd. to enhance its health service system[19]. - The company’s subsidiary received approval for a clinical trial for a new drug targeting HPV-related conditions, showcasing ongoing R&D efforts[19]. - Research and development expenses for the current period were ¥10,024,839.12, down from ¥10,877,646.84 in the previous period, a decrease of 7.8%[28]. Other Income and Expenses - The company reported a significant increase of 96.91% in other income to ¥2,066,921.45, primarily due to increased government subsidies[10]. - Investment losses for Q1 2025 were ¥3,976,605.05, a 124.02% increase compared to losses of ¥1,775,111.21 in the previous year, mainly due to a decline in net profits from joint ventures[10]. - Total operating costs decreased to ¥99,442,024.53 from ¥106,513,804.78, reflecting a reduction of 6.3%[27].